Wedbush maintains an Outperform rating on OncoGenex Pharmaceuticals (Nasdaq: OGXI), raises price target from $40 to $56.

Wedbush analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE